SiBionics CGM GS3
At the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Vienna on September 21, 2025, SiBionics presented its integrated Continuous Glucose Monitoring (CGM) and Continuous Ketone Monitoring (CKM) diabetes management solution. The company’s innovative approach received widespread recognition from top researchers in the field, sparking discussions on its potential to transform diabetes care.
The symposium, themed “CGM + CKM for Better Diabetes Management,” featured prominent experts, including co-chairs Prof. Linong Ji from Peking University People’s Hospital and Prof. Stefano Genovese from Italy. Other notable speakers included Prof. Andrej Janež from Slovenia, Prof. Nina Jendrike from Germany, and Dr. Yifei Mo from China. These experts shared recent academic research findings, highlighting the significance of continuous monitoring technologies in diabetes management.
On the exhibition floor, SiBionics showcased its next-generation devices, the GS3 Continuous Glucose Monitoring (CGM) system and the KS3 Continuous Ketone Monitoring (CKM) device. These innovations attracted considerable interest from conference attendees, who engaged actively with the SiBionics team. Visitors inquired about the products’ technical strengths and their relevance in real-world diabetes management.
A recent feasibility study confirmed that SiBionics’ solutions meet and even exceed the standards set by the integrated CGM (iCGM) criteria across several key performance indicators. The GS3 system, in particular, demonstrated remarkable accuracy, especially in the hypoglycemic range, surpassing iCGM requirements. This reinforces its value in aiding clinical decision-making and supporting patient self-management.
SiBionics is positioned as a leader in continuous monitoring technologies, currently the only company globally to commercialize CKM. The company’s strong research and development capabilities, combined with its pioneering vision, are set to drive further innovation in diabetes care.
Looking ahead, SiBionics plans to expand its continuous monitoring portfolio, aiming to enhance health outcomes for individuals living with diabetes worldwide. Founded in 2015 and headquartered in Shenzhen and Irvine, SiBionics specializes in biosensor innovation, merging continuous monitoring technology with smart algorithms and user-friendly software. With a workforce of over 500 employees, 25% of whom are dedicated to research and development, SiBionics is committed to advancing personalized, data-driven healthcare solutions.
